Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
9201
PUT
ARS Pharmaceuticals
SPRY
$577M
| $373K | ﹤0.01% |
+88,000
| New | +$307K |
|
9202
CALL
Sportradar
SRAD
$4B
| $373K | ﹤0.01% |
47,200
-40,500
| -46% | -$443K |
|
9203
CALL
Accel Entertainment
ACEL
$996M
| $372K | ﹤0.01% |
35,000
+11,800
| +51% | +$132K |
|
9204
CALL
Badger Meter
BMI
$3.74B
| $372K | ﹤0.01% |
4,600
-300
| -6% | -$24.8K |
|
|
DENN
9205
CALL
DELISTED
Denny's
DENN
| $372K | ﹤0.01% |
42,800
+14,400
| +51% | +$159K |
|
9206
Inogen
INGN
$151M
| $372K | ﹤0.01% |
+15,389
| New | +$409K |
|
9207
CALL
State Street SPDR S&P Capital Markets ETF
KCE
$478M
| $372K | ﹤0.01% |
5,100
+1,800
| +55% | +$144K |
|
|
DEN
9208
PUT
DELISTED
Denbury Inc.
DEN
| $372K | ﹤0.01% |
6,200
-11,100
| -64% | -$789K |
|
|
JHMF
9209
DELISTED
John Hancock Multifactor Financials ETF
JHMF
| $372K | ﹤0.01% |
+8,739
| New | +$407K |
|
9210
ARK Space & Defense Innovation ETF
ARKX
$866M
| $371K | ﹤0.01% |
27,598
-47,664
| -63% | -$721K |
|
|
IQIN
9211
DELISTED
NYLI 500 International ETF
IQIN
| $371K | ﹤0.01% |
13,640
-18,892
| -58% | -$564K |
|
|
ICOL
9212
DELISTED
iShares MSCI Colombia ETF
ICOL
| $371K | ﹤0.01% |
+41,206
| New | +$461K |
|
9213
Amalgamated Financial
AMAL
$1.52B
| $370K | ﹤0.01% |
18,692
-16,558
| -47% | -$319K |
|
9214
California Resources
CRC
$4.72B
| $370K | ﹤0.01% |
9,621
-35,800
| -79% | -$1.53M |
|
9215
CALL
ING
ING
$102B
| $370K | ﹤0.01% |
37,300
-2,000
| -5% | -$20.4K |
|
9216
CALL
MDU Resources
MDU
$4.33B
| $370K | ﹤0.01% |
36,029
| – | – |
|
9217
NBT Bancorp
NBTB
$2.77B
| $370K | ﹤0.01% |
+9,831
| New | +$356K |
|
9218
PUT
Tronox
TROX
$931M
| $370K | ﹤0.01% |
22,000
+5,100
| +30% | +$92.4K |
|
9219
CALL
ACV Auctions
ACVA
$1.34B
| $369K | ﹤0.01% |
56,400
-34,000
| -38% | -$350K |
|
|
ADN
9220
DELISTED
Advent Technologies
ADN
| $369K | ﹤0.01% |
4,878
+1,278
| +36% | +$77.1K |
|
9221
Mission Produce
AVO
$1.15B
| $369K | ﹤0.01% |
25,895
+11,079
| +75% | +$148K |
|
9222
CALL
Crescent Capital BDC
CCAP
$401M
| $369K | ﹤0.01% |
23,800
+4,100
| +21% | +$70.3K |
|
9223
PUT
Corcept Therapeutics
CORT
$12.6B
| $369K | ﹤0.01% |
15,500
-33,900
| -69% | -$739K |
|
9224
Arrow Dow Jones Global Yield ETF
GYLD
$37.5M
| $369K | ﹤0.01% |
28,382
+6,323
| +29% | +$87.7K |
|
9225
CALL
Insmed
INSM
$27.7B
| $369K | ﹤0.01% |
18,700
-5,100
| -21% | -$107K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.